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SUMMARY
Introduction. It is estimated that 30% of people with epilepsy continue to have seizures despite treat-
ment. The approval of many new antiseizure drugs during the past two decades has not substantially re-
duced the proportion of patients with medically refractory disease. Patients need new treatments. Many 
families choose to try alternative therapy options. An abundance of preclinical evidence and anecdotal 
human data support the use of cannabinoids in the treatment of epilepsy.
Aim. The present review paper aims to present the current state of knowledge regarding the effectiveness 
and safety of cannabinoids in the treatment of epilepsy.
Material and methods. This review covers the most relevant and recent papers identified using the Pub-
Med database.
Results and discussion. Cannabidiol has shown anticonvulsant activity in many acute animal models of 
seizures. Recently three well controlled randomized trails focused on the potential usefulness of cannabi-
noids in the treatment of epilepsy have been published. Based on these publications, the US Food and 
Drug Administration approved in 2018 a purified, plant-derived cannabinoid for the treatment of seizures 
in patients with Dravet syndrome and Lennox-Gastaut syndrome.
Conclusion. An abundance of preclinical evidence and anecdotal human data support the use of can-
nabinoids in the treatment of epilepsy. Recently purified, plant-derived cannabinoid was approved for the 
treatment of seizures in patients with Dravet syndrome and Lennox-Gastaut. Additional data are needed 
to determine the long-term efficacy and safety of cannabidiol for severe epilepsy syndromes
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INTRODUCTION
Epilepsy is one of the most common disorders of the 
nervous system. It is a health problem as well as a so-
cial and economic one. Epilepsy affects over 65 mil-
lion people worldwide (CDC, 2012). Patients who suf-
fer from seizures in spite of the administration of two 
subsequent, appropriately-selected antiepileptic drugs 
(AEDs) that are well applied and tolerated, are diag-
nosed with refractory epilepsy (Kwan et al., 2010). It is 
estimated that 30% of people with epilepsy continue 
to have seizures despite treatment (Brodie et al., 2012; 
Kwan, Brodie, 2000). The approval of many new an-
tiseizure drugs during the past two decades has not 
substantially reduced the proportion of patients with 
medically refractory disease (Brodie et al., 2012). The 
safety and side-effect profile of antiseizure drugs has 
improved, but side effects related to the central nervous 
system are common and affect quality of life (Perucca, 
Gilliam, 2012). Patients need new treatments that con-
trol seizures and have fewer side effects. Many families 
choose to try non-pharmaceutical or alternative thera-
py options. Cannabis-based treatment for epilepsy has 
recently received prominent attention in the lay press 
and in social media. The reports of dramatic improve-
ments in seizure control in children with severe epilep-
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sy have been published (Gupta, 2013). An abundance of 
preclinical evidence and anecdotal human data support 
the use of cannabinoids in the treatment of epilepsy.
AIM
The present review paper aims to present the current 
state of knowledge regarding the effectiveness and 
safety of cannabinoids in the treatment of epilepsy in 
humans.
MATERIAL AND METHOD
This review covers the most relevant recent papers iden-
tified using the PubMed database. The search was con-
ducted in June 2019 and included the terms: cannabi-
noids, epilepsy, treatment, cannabidiol (CBD), tetrahy-
drocannabinol (THC) It encompasses articles published 
in English from 2010 to 2019. Randomized controlled 
trails and reviews was included. Other types of studies 
were excluded. Also, additional relevant publications 
were identified within the various references highlight-
ed within the original papers.
RESULTS AND DISCUSSION
THC and CBD
Cannabis has been used by humanity in a variety of 
medical settings via a range of different formulations 
for more than 5000 years. The plant Cannabis sativa, 
commonly known as marijuana, is composed of more 
than 500 compounds and new components continue 
to be discovered (Radwan et al., 2009). Although there 
are many preparations with cannabinoids only some of 
them are being investigated and developed as anticon-
vulsants. These biologically active compounds isolated 
from the cannabis plant are termed phytocannabinoids. 
The best studied of these are Δ9-tetrahydrocannabinol 
(THC) and cannabidiol (CBD) and their metabolites. 
More recently, trials have begun with Cannabidiva-
rin (CBDV). CBDV has similar molecular structure to 
CBD but instead of having a pentyl chain, it has a pro-
pyl chain. This propyl cannabinoid has slightly differ-
ent properties than CBD. CBD was isolated in 1940 and 
its structure was elucidated in 1963, whereas THC was 
isolated and characterized in 1964 (Mechoulam, Shvo, 
1963). In the late 1980s it was found that THC canbind 
to two G-protein-coupled cell membrane receptors, 
consequently named the cannabinoid type 1 (CB1) and 
type 2 (CB2) receptors, to exert its effects. The discov-
ery of cannabinoid receptors in the CNS led to a search 
for endogenous substances interacting with these re-
ceptors. These endogenous counterparts of phytocan-
nabinoids, are known as endocannabinoids. The most 
important of which are the arachidonic acid deriva-
tives anandamide (2-arachidonoylethanolamide) and 
2-arachidonoyl glycerol (Reddy, Golub 2016). These en-
docannabinoids are produced on demand during ex-
cessive neuronal excitation. Despite overt differences 
in their chemical structures, phytocannabinoids share 
three-dimensional aspects of their structure with en-
docannabinoids (Maccarrone et al., 2017; Chiurchiu et 
al., 2018). This resemblance is the reason why phyto-
cannabinoids can bind the same targets that are recog-
nised by endocannabinoids. Phytocannabinoids, unlike 
the endocannabinoids, have terpenophenolic structures 
because they cannot be synthesised nor hydrolysed by 
the body. It is important because the biological activ-
ity of endocannabinoids is tightly regulated through 
metabolic control (Iannotti et al., 2016; Maccarrone 
et al., 2015). THC possible use as an antiepileptic drug 
(AED) in humans has been hindered by its known psy-
chotropic effects. CBD and CBDV are lacking these 
complicating properties (Rosenberg et al., 2015). Un-
like THC, CBD does not activate CB1 and CB2 recep-
tors. However, CBD interacts with many other, non-en-
docannabinoid signaling systems. It is a called “multi-
target” drug (Devinsky et al., 2014). The plausible and 
implausible CBD’s molecular targets as well as the po-
tential pharmacological effects of CBD in neurological 
disorders including epilepsy has been reviewed else-
where (Ibeas Bih et al., 2015). It is believed that its an-
ticonvulsant action of cannabidiol is associated with at 
least some of the following mechanisms: stimulation 
of 5-HT1a receptors, inhibition of glutamate release, 
inhibition of noradrenaline, dopamine and adenosine 
reuptake, stimulation of glycine receptors and stimula-
tion and desensitization of transient receptor potential 
class channels (ankyrin and vanilloid types, i.e. TRPA1, 
TRPV1 and TRPV2 receptors) (Leo et al., 2016). An-
ticonvulsant effect of CBDV is, similar as CBD, prob-
ably related to its agonistic action on TRPA1, TRPV1 
and TRPV2, while its inhibitory action on diacylglyc-
erol lipase-α, which synthesizes 2-arachidonoylglyc-
erol, an endocannabinoid, remain yet to be connect-
ed to anticonvulsant properties (Hill et al., 2013; Ian-
notti et al., 2014).
Preclinical data and anecdotal reports
In the late 19th century, prominent English neurologists 
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including Reynolds (Reynolds, 1861) and Gowers (Gow-
ers, 1881) used cannabis to treat epilepsy. However, the 
use of cannabis for epilepsy remained very limited, and 
despite anecdotal successes, cannabis received scant or 
no mention from English language epilepsy texts in 
the late 19th and early to mid-20th centuries. Some an-
ecdotal reports suggest that cannabis has antiepileptic 
properties and would be effective to manage focal epi-
lepsies and generalized tonic-clonic seizures, however, 
also seizure exacerbation after cannabis use has been 
observed (Detyniecki, Hirsch, 2016).
The two cannabinoids that have been mostly used in 
treating epilepsy are THC and CBD. Many early stud-
ies focused on THC. The results of these studies dem-
onstrated mixed efficacy in acute seizure models in 
various species (Andrew et al., 2013). In some models, 
THC reduced seizure frequency or severity, whereas 
in other studies there was no effect. Even in some na-
ive, seizure-susceptible rats and rabbits, THC actually 
provoked epileptiform activity (Stadnicki et al., 1974; 
Martin, Consroe, 1976). These findings suggest that 
activation of CB1 receptors is unlikely to yield thera-
peutic benefit for patients with epilepsy (Devinsky et 
al., 2014). As highlighted earlier, the use of THC was 
limited due to its known psychotropic effects. CBD 
has shown anticonvulsant activity in many acute an-
imal models of seizures, whereas few data and no da-
ta are present respectively in animal models of chron-
ic epilepsy and as well as in animal models of epilep-
togenesis (Devinsky et al., 2014; Santos et al., 2015). In 
these preclinical experimental studies, CBD has been 
effective similarly to the AEDs used in clinical thera-
py (Scuderi et al., 2009). However, CBD mechanisms 
of action are complex and as yet not entirely clear. Tri-
als with CBDV are still underway.
Safety
Much of the available data regarding the safety and side-
effect profile of cannabinoids, especially with long-term 
use, come from studies examining the effects of rec-
reational use (Hall, Solowij, 1998; Volkow et al., 2014). 
The endocannabinoid system undergoes development 
in childhood and adolescence. Long-term exposure to 
marijuana may lead to cognitive and behavioral chang-
es. In long-term adult users imaging studies of the brain 
revealed altered structure and function of the prefron-
tal cortices and precuneus (Volkow et al., 2014) and de-
creased volume in the hippocampi and amygdalae (Lo-
renzetti et al., 2015). Until more data become available, 
the neurodevelopmental risks of cannabinoid-based 
therapies should be weighed against the potential ben-
efits for seizure control. Long-term recreational use of 
cannabis is associated with a risk of dependence, but 
little is known regarding the potential for the abuse of 
cannabinoid-based treatments when they are used in 
a clinical practice (Volkow et al., 2014). Some safety con-
cerns have been raised with regard to the pharmacoki-
netic interactions of cannabinoids in patients with ep-
ilepsy who are long-term users. Cannabinoids can in-
hibit cytochrome P-450 (CYP) enzymes which help to 
metabolize many AEDs (Patsalos, Perucca, 2003). This 
inhibition can potentiate drug efficacy and toxicity. 
CBD is metabolized through the P-450 system and is 
a potent inhibitor of CYP2C9, CYP3A4 and CYP2C19 
(Stout, Cimino 2014; Zendulka et al., 2016). The situa-
tion with CBDV is still unclear, although a similar ad-
verse pharmacokinetic scenario is likely.
These isoenzymes are induced by AEDs, such as car-
bamazepine, topiramate, and phenytoin, and are in-
hibited by others, such as valproate (Patsalos, Peruc-
ca, 2003). The potential for drug-drug interactions be-
tween antiseizure drugs and cannabinoids may be bi-
directional. It was shown that cannabidiol can raise 
the serum levels of the N-desmethyl metabolite of 
clobazam, which can have antiseizure and sedative ef-
fects. (Friedman et al., 2014). This interaction is like-
ly to be clinically important since patients prescribed 
clobazam are more likely to experience sedation with 
cannabidiol than those not taking clobazam (Devinsky 
et al., 2015). The antiseizure effect of CBDV is similar 
to CBD not mediated by CB1 receptors and both these 
molecules possibly have other unique mechanisms of 
action (Iannotti et al., 2014).
Patient’s belief and scientific evidence
Another obstacle to scientific inquiry into cannabinoids 
for the treatment of epilepsy is the perception among 
many patients and caregivers that sufficient evidence 
of their safety and efficacy already exists (Mathern et 
al., 2015). The gap between patient beliefs and availa-
ble scientific evidence highlights a set of factors that 
confound cannabinoid research and therapy. One of 
them is the naturalistic fallacy. It is the belief that na-
ture’s products are safe. Other gaps are the conversion 
of anecdotes and strong beliefs into facts and failure to 
appreciate the difference between research and treat-
ment (Henderson et al., 2007). It is worthy to mention 
one study of children with epilepsy in Colorado (Press 
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et al., 2015). In this trial the rate of response to thera-
py reported by parents who had moved their family to 
the state to receive cannabinoid therapy was more than 
twice as high as that reported by parents who were al-
ready residing in the state (47% vs 22%) (Press et al., 
2015). This finding suggests that the stronger the be-
lief that the drug will be beneficial and the greater the 
sacrifice involved to obtain the drug, the greater the 
reported response.
Placebo response rates are high among children and 
adolescents with a wide variety of conditions (Weimer 
et al., 2013) The issue of high response rates to place-
bos in studies of children is especially relevant to epi-
lepsy and emphasizes the importance of placebo-con-
trolled trials. According to results of metaanalysis per-
formed among patients with treatment-resistant focal 
epilepsy, children had more improvement with place-
bo than did adults (19.9% vs 9.9%), although there was 
no significant difference in the response to active treat-
ment (Rheims et al., 2008). Moreover, children with in-
tellectual disability and severe epilepsy are especially 
prone to elevated response rates to placebo. It should 
be emphasized that contrary to belief of some patients 
and their caregivers the efficacy in treatment of epilep-
sy was proved only for purified, plant-derived cannab-
inoid, named cannabidiol (FDA, 2018). Unfortunately, 
different marijuana strains have varying amounts of 
THC and CBD. The improvement after the introduc-
tion of CBD extracts followed by seizure worsening 
in two children with treatment-resistant epilepsy af-
ter a short time with associated signs of toxicity from 
THC has been recently described (Crippa et al., 2016). 
In both children, a rapid improvement symptom of 
toxicity with seizure remission in both of children oc-
curred when purified CBD replaced the extract with no 
THC. The pharmacological potency of THC is much 
higher than that of CBD, and it can produce toxicity 
in a much smaller dose. This highlighted the need for 
well-standardized formulations with fixed high CBD 
and low THC concentrations for the treatment of epi-
lepsy. Patients and their caregivers should be aware of 
using cannabinoids from unknown sources. Marijua-
na used for recreational purposes may not only be not 
effective but even dangerous in patients with epilepsy.
Results of controlled studies
To-date only two of the investigational cannabinoids 
were tested in clinical trials on patients with epilepsy; 
cannabidiol and cannabidivarin (Bialer et al., 2017). In 
the 1970s and 1980s four placebo-controlled studies of 
the use of cannabinoids for the treatment of epilepsy 
have been undertaken (Ames, Cridland, 1985; Cunha 
et al., 1980; Mechoulam, Carlini, 1978; Trembly, Sher-
man, 1990). In the first one, 15 patients with temporal 
lobe epilepsy and secondary generalized seizures, not 
well controlled by standard AEDs, were enrolled and 
randomized in groups treated in addition to their ha-
bitual AED therapy with CBD (200–300 mg per day, per 
os) or placebo. Study duration was 4.5 months. Of the 
8 CBD treated patients, four became and remained sei-
zure-free during the treatment with CBD (8–18 weeks), 
three exhibited a clinical improvement, while the oth-
er CBD treated patients did not improve. In the place-
bo group, 6 out of 7 patients remained unchanged and 
one has shown a clinical improvement. Drowsiness was 
reported by 4 patients on CBD. No severe side effects 
were reported (Cunha et al., 1980). In the second study, 
12 patients with uncontrolled seizures and intellectual 
disability were divided in two groups treated with three 
capsules of sunflower oil (as placebo) or three capsules 
of sunflower oil and 100 mg of CBD for the first week. 
During the following three weeks, patients received two 
capsules per day. No differences in seizure frequency 
between the two groups were found. The only side ef-
fect was mild drowsiness (Ames, Cridland, 1985). In 
the third study, 9 patients with uncontrolled epilepsy 
in addition to their habitual AED therapy were treated 
with 200 mg daily of CBD or placebo. Study duration 
was three months. Two of 4 patients treated with CBD 
achieved seizure freedom, during the three months of 
treatment; one had only partial improvement, where-
as the last one had not shown beneficial clinical effects. 
None of the patients treated with placebo had clinical 
improvement. No side effects were detected (Mechou-
lam, Carlini, 1978). The fourth trial was only present-
ed at a conference. In this study, 12 patients were treat-
ed with a single-blind placebo for 6 months followed by 
double-blind 300 mg of CBD or placebo in a cross-over 
trial design. No statistics were performed. According to 
preliminary data analysis there was some reduction in 
seizure frequency (Trembly, Sherman, 1990). All four 
studies were considerably underpowered and had meth-
odologic problems, including the small sample size and 
lack of blinding. All these results were summarized in 
a Cochrane review which concluded that “no reliable 
conclusions can be drawn at present regarding the effi-
cacy of cannabinoids as a treatment for epilepsy” (Gloss, 
Vickrey, 2014). This assessment was confirmed in a sys-
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tematic review by the American Academy of Neurolo-
gy (Koppel et al., 2014). Physicians have to be “evidence 
based” which entails undertaking randomized, double-
blinded, placebo-controlled clinical trials (RCT). It is 
imperative that studies are blinded and well designed.
Recently three well controlled randomized trials fo-
cused on the potential usefulness of cannabinoids in 
the treatment of epilepsy have been published (Devin-
sky et al., 2015; Devinsky et al., 2017; Devinsky et al., 
2018; Thiele et al., 2018). The first completed trial eval-
uated the efficacy of a purified oral CBD solution in 
214 patients with severe, intractable, childhood-onset 
treatment resistant epilepsy. The aim of this open la-
beled study was to establish whether the addition of 
cannabidiol to existing AED regimens would be safe, 
well tolerated, and efficacious in children and young 
adults with treatment-resistant epilepsy. The prima-
ry endpoint was to establish the safety and tolerability 
of cannabidiol (administered orally and starting from 
2–5 mg/kg and up-titrated to 25–50 mg/kg per day), 
and the primary efficacy outcome was median percent-
age change in the mean monthly frequency of motor 
seizures at 12 weeks. The median change in monthly 
motor seizures from baseline was – 36.5% (IQR – 64.70 
to 0). The adverse event profile of cannabidiol was fa-
vorable, with mAEDs. Common adverse events includ-
ed somnolence, diarrhea, fatigue, and decreased appe-
tite. Only 5 of 162 patients stopping treatment because 
of an adverse event. The results of this trial suggest 
that cannabidiol might reduce seizure frequency and 
might have an adequate safety profile in children and 
young adults with highly treatment-resistant epilepsy 
(Devinsky et al., 2015).
A subsequent trial enrolled 120 children with Dravet 
syndrome, aged 2–18 years, who experienced four or 
more convulsive seizures per month despite receiving 
one or more AEDs. The primary end point was the 
change in convulsive-seizure frequency over a 14-week 
treatment period, as compared with a 4-week baseline 
period. Patients treated with cannabidiol (adminis-
tered orally in daily doses up to 20 mg/kg per day), had 
a significantly greater reduction in seizures per month 
(12.4 seizures at baseline to 5.9 seizures) then in placebo 
group (14.9 seizures at baseline to 14.1 seizures). The ad-
verse-event profile of cannabidiol in this trial was sim-
ilar to that in the previous open-label trial (Devinsky et 
al., 2015). This trial showed that cannabidiol resulted 
in a greater reduction in convulsive-seizure frequency 
than placebo among children and young adults with 
drug-resistant Dravet syndrome (Devinsky et al., 2017).
There have been two trials enrolling patients with 
Lennox-Gastaut syndrome (Thiele et al., 2018; Devin-
sky et al., 2018). The first randomized, double-blind tri-
al to assess the efficacy and safety of cannabidiol (ad-
ministered orally in 20 mg/kg daily dose) as add-on 
anticonvulsant therapy for patients with Lennox-Gas-
taut syndrome was the GWPCARE4 study. Patients in 
this study were highly treatment resistant. At baseline 
they had a median 73.8 drop seizures every 28 days de-
spite current treatment with three or more concomitant 
AEDs. Even in this highly treatment-resistant popula-
tion, statistically significant and clinically meaning-
ful improvements in seizure frequency were observed 
following the addition of cannabidiol to existing AED 
regimens compared with placebo. Patients treated with 
cannabidiol had a significantly greater reduction in sei-
zures per month (74.8 seizures at baseline to 31.4 sei-
zures) then in placebo group (74.7 seizures at baseline 
to 5.3 seizures). In the cannabidiol group, the monthly 
frequency of drop seizures decrease was greater than 
in the placebo group. The observed tolerability pro-
file for cannabidiol was consistent with that reported 
in a previous open-label trials (Devinsky et al., 2015). 
In this trial, a 20 mg/kg daily dose of cannabidiol as 
add-on therapy to existing AEDs significantly reduced 
the frequency of drop, non-drop, and total seizures in 
highly treatment-resistant patients with Lennox-Gas-
taut syndrome (Thiele et al., 2018). The results of this 
trial were replicated in a further trial comprising chil-
dren and adults with the Lennox-Gastaut syndrome. In 
this study the addition of cannabidiol at a dose of 10 
mg or 20 mg per kilogram per day to a conventional 
AED regimen resulted in greater reductions in the fre-
quency of drop seizures compared to placebo (Devin-
sky et al., 2018). On the basis of above highlighted tri-
als, the US Food and Drug Administration (FDA) ap-
proved in 2018 a purified, plant-derived cannabinoid, 
named cannabidiol, for the treatment of seizures in pa-
tients with Dravet syndrome and Lennox-Gastaut syn-
drome (FDA, 2018).
Despite positive results in these two severe epilepsy 
syndromes, further studies are needed to determine if 
the anti-seizure effects of cannabidiol extend to oth-
er forms of epilepsy. Such trials are currently ongoing. 
Cannabidivarin is currently being tested in two phase 
II clinical trials aimed to evaluate its pharmacokinetics, 
safety and tolerability compared to placebo, as add-on 
therapy in patients (aged 18–65 years) with inadequate-
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ly controlled focal seizures. The studies are completed 
but results are not published yet. The studies are reg-




An abundance of preclinical evidence and anecdotal 
human data support the use of cannabinoids in the 
treatment of epilepsy. Recently purified, plant-derived 
cannabinoid, named cannabidiol was approved for 
the treatment of seizures in patients with Dravet syn-
drome and Lennox-Gastaut. The adverse event profile 
of cannabidiol is favorable, with most patients tolerat-
ing the drug well. The mechanism of antiepileptic ac-
tion of cannabinoids in epilepsy is not exactly known 
and should be elucidated in the future. In addition, it 
is not known how to produce a formulation with con-
sistent pharmacokinetics suitable for a major clinical 
trial program; it is not know whether cannabinoids 
will make a major difference in the lives of most peo-
ple with pharmacoresistant epilepsy and those who 
care for them; it is not known why a few patients ap-
pear to have a miraculous response to cannabis deriv-
atives. Is there a genetic reason for this? (Brodie, Ben-
Menachem, 2018). Additional data are needed to deter-
mine the long-term efficacy and safety of cannabidiol 
for severe epilepsy syndromes (Devinsky et al., 2015; 
Devinsky et al., 2017).
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